Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


June 02, 2015 4:03 PM ET

Biotechnology

Company Overview of X-BODY, Inc

Company Overview

X-BODY, Inc., a biotechnology company, develops a platform for the generation of monoclonal antibody therapeutics by interrogation of human libraries and deep sequencing. The company discovers and develops compounds against biologically relevant targets in oncology and ophthalmology. It also develops screening system that is applicable for various processes, such as generation of soluble VH domains, Fabs, IgGs, and bispecifics; selection against cell surface targets on live cells, including selections for function; affinity maturation; identification of stable VH-VL pairs; and epitope discovery by differential screening of live cells and other samples. X-BODY, Inc. was founded in 2008 and is...

100 Beaver Street

Waltham, MA 02453

United States

Founded in 2008

Phone:

781-891-0029

Key Executives for X-BODY, Inc

Co-Founder, Executive Chairman, Chief Executive Officer and President
Co-Founder and Director
Co-Founder and Director
Age: 76
Chief Business Officer
Age: 49
Senior Vice President of R&D
Compensation as of Fiscal Year 2014.

X-BODY, Inc Key Developments

Kindred Biosciences and X-Body Biosciences Announce an Exclusive Collaboration for Discovery of Antibodies for Companion Animal Health

Kindred Biosciences, Inc. and X-Body Biosciences jointly announced an exclusive alliance in which X-Body will discover fully canine, feline, and equine antibodies for companion animal health, and Kindred Bio will develop and commercialize these antibodies. Kindred Bio will provide an upfront payment, research funding, milestones, and royalties, and X-Body will exclusively license these antibodies to Kindred Bio. X-Body will use its proprietary DNA-antibody technology and live cell functional selection technology to generate therapeutic antibodies and Kindred Bio will develop these antibodies to address unmet medical needs in companion animal health. X-Body's antibody technology is based on a method of linking an antibody to its gene, combined with a cell-free mammalian translational system, allowing rapid generation and screening of antibodies, as well as identification of bispecific antibodies. Its live cell selection technology can identify antibodies against membrane-bound targets.

Similar Private Companies By Industry

Company Name Region
GenoPlex, Inc. United States
Preventive Medical Technologies United States
Gulf Nuclear of Louisiana Inc. United States
Click Therapeutics, Inc. United States
Affomix Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact X-BODY, Inc, please visit www.x-bodybiosciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.